MannKind Corporation (NASDAQ:MNKD) submits application to FDA for pediatric use of Afrezza, supported by positive trial results. Company also progressing pipeline in respiratory and rare diseases. Secures $500M financing from Blackstone to accelerate launch of pediatric Afrezza and advance clinical programs for growth in diabetes care and specialty lung disease markets.

Read more at Yahoo Finance: MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline